Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
Provided By PR Newswire
Last update: Mar 4, 2025
- STAR-1 topline results expected by the end of March 2025 -
- Over 30 million acne patients seek treatment in the U.S. each year -
- XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S.
and Latin America -
